Navigation Links
Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
Date:10/13/2008

In a randomized controlled trial called the "Evaluate the Clinical use of vitamin K Supplementation in Postmenopausal Women with Osteopenia" (ECKO) trial, Angela Cheung and colleagues at the University of Toronto found that a high dose daily vitamin K1 supplement did not protect against age-related bone mineral density (BMD) decline. However, as reported in this week's PLoS Medicine, the findings also suggest that vitamin K1 may protect against fracture and cancer in postmenopausal women with osteopenia.

Dr. Cheung and colleagues randomized 440 postmenopausal women with osteopenia to receive either 5 mg of vitamin K1 or a placebo daily for two years. Two hundred and sixty one of these women continued their treatment for two more years to gather information about the long-term effects of vitamin K1 supplementation.

After two years and after four years, lower back and hip measurements of bone mineral density (BMD) had decreased by similar amounts in both the vitamin K and the placebo groups.

Over the four-year period, fewer women in the vitamin K group had fractures (9 versus 20 women in the placebo group) and fewer women had cancer (3 versus 12). Vitamin K supplementation was well tolerated over the four-year period and adverse health effects were similar in the two treatment groups, report the researchers. They emphasize that the study was not powered to examine fractures or cancers and the numbers were small, therefore the findings must be interpreted with caution.

The researchers say that larger studies are needed to examine the effect of vitamin K1 on fractures and on cancer and, until these are done, high dose vitamin K1 supplementation should not be recommended for the prevention of osteoporosis.

In the US, 10 million people have osteoporosis and 18 million have osteopenia, a milder condition that precedes osteoporosis.


'/>"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Lack of vitamin D linked to Parkinsons disease
2. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
3. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
4. Dont forget the vitamin A when working with its carrier protein
5. Variant of vitamin D receptor gene linked to melanoma risk
6. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
7. Vitamin A pushes breast cancer to form blood vessel cells
8. Researchers identify cancer preventive properties in common vitamin supplement
9. Newborn vitamin A reduces infant mortality
10. New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections
11. Vitamin D: New way to treat heart failure?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. ... testing solutions for the detection of foodborne pathogens,  today announced ... Sidoti & Company Spring 2017 Convention on March 29 at ... York Marriott Marquis. About Roka Bioscience ... Roka ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... , ... March 27, 2017 , ... PMG Research ... Collaborations (CTC) conference presented by The Conference Forum in Boston on April 3-4, ... collaborate to drive improved clinical trial outcomes and bring them closer to the patient. ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 /PRNewswire/ ... company developing novel therapies for neurodegenerative diseases, including ... confirmation that its application to list the Company,s ... been approved by The NASDAQ Stock Market, a ... of the listing, Neurotrope will ring the Opening Bell ...
Breaking Biology Technology: